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1340Moreover, we have previously addressed this in our other publica-
tions (1,2). Of note, in the absence of a control group, we make no
conclusion in our report (3) about who should undergo carotid
revascularization in the face of imminent OHS. Rather, we
present the risk involved with each of the 3 common approaches
when a decision has already been made to treat severe disease in
both territories. In general, it would be most appropriate to perform
carotid revascularization in patients considered at “high risk” for
stroke, such as those with symptomatic carotid disease, bilateral severe
carotid stenosis, contralateral carotid occlusion or severe asympto-
matic carotid stenosis accompanied by impaired cerebral perfusion
reserve, transcranial Doppler microemboli, or magnetic resonance
imaging evidence of complicated carotid plaque. An algorithmic
approach to the management of concomitant severe carotid and cor-
onary artery disease has been previously published by our group (1,2).
We disagree with Dr. Naylor’s comments regarding the editorial
for the same reasons. We strongly believe that our analyses provide
more clarity for clinicians amid the available conﬂicting evidence
(4). We addressed many of the limitations of previous publications
by accounting for interstage events, adjusting for multiple con-
founders, and examining the early and late risk associated with
treating both territories. Clearly, once a decision has been made to
treat the carotid disease in patients undergoing OHS, the staged
approach of carotid artery stenting and OHS is superior to the
other 2 approaches. In the absence of level 1 evidence, the role of
carotid revascularization in this population will remain debatable.
In the meantime, we anticipate that real-world practice will change
in favor of careful patient selection (on the basis of “high-risk”
features as described previously) and treated according to the best
available evidence.
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Intravenous Abciximab
Bolus AdministrationWe read with interest the recently published paper by Desch et al.
(1) reporting on long-term clinical follow-up of the randomized
AIDA STEMI (Abciximab i.v. Versus i.c. in ST-elevation
Myocardial Infarction) trial.
The AIDA STEMI trial failed to demonstrate a signiﬁcant dif-
ference in a composite endpoint of major adverse cardiac events
(MACE) between intracoronary and intravenous abciximab
administration at short-term follow-up (2). However, a low event
ratewas registered in the trial, whichwas consequently underpowered
for evaluation of clinical events. In a recentmeta-analysis of 5 studies,
including the AIDA STEMI trial, we found a signiﬁcantly lower
incidence ofMACE at short-term follow-up (odds ratio [OR]: 0.56;
95% conﬁdence interval [CI]: 0.35 to 0.89; p ¼ 0.015) (3).
In light of the newly published long-term results of the AIDA
STEMI trial, the largest trial ever published, we updated the meta-
analysis and found no signiﬁcant difference in the incidence of
MACE (OR: 0.63; 95% CI: 0.37 to 1.08; p ¼ 0.091) or death
(OR: 0.63; 95% CI: 0.27 to 1.47; p ¼ 0.286) at long-term follow-
up (Figs. 1A and 1B).
Is this, then, the de profundis of intracoronary abciximab delivery?
Surely, the idea that intracoronary delivery of the abciximab bolus
could lead to a more effective acute antiplatelet action than usual
intravenous administration still remains attractive, and a number of
biologically plausible mechanisms have been proposed to explain
such an effect (4). The authors themselves ﬁnd these negative re-
sults surprising, given that previous studies reported a clear beneﬁt
on a number of surrogate markers (1). Nevertheless, the currently
available clinical evidence seems not to support this concept. Un-
doubtedly, the question remains whether this is the real answer
to the question of a better clinical effectiveness of intracoronary
abciximab bolus administration. Can these unsatisfactory results
be explained differently?
The authors probably counted on a higher event rate when
designing the study. However, the AIDA STEMI trial was un-
derpowered to detect a signiﬁcant difference, given the low event
rate registered in the trial for both treatment groups, which was
probably a consequence of the all-comers design of the trial. In fact,
the mean baseline left ventricular ejection fraction (LVEF) was
>50% in the AIDA STEMI trial, suggesting a small mean infarct
size and consequently a low-risk cohort. Accordingly, and in line
with our previous results showing in the subgroup analysis that most
evidence of beneﬁt was coming from those studies with a main
baseline LVEF<50% (3), a meta-regression analysis of all currently
available studies reporting on long-term clinical endpoints showed a
signiﬁcant relationship (p¼ 0.012) between the treatment effect and
the mean LVEF of the single studies (Fig. 1C). In other words, a
beneﬁt is evident that increases as the mean LVEF decreases.
Thus, although no ﬁnal conclusion can be drawn about the
theorized beneﬁt of direct intracoronary abciximab administration
on clinical endpoints, the failure to demonstrate such beneﬁt in the
AIDA STEMI trial can be related to the selection of a low-risk
population. This ﬁnding can be explained through the so-called
Figure 1 Meta Analysis of Studies on IC Abciximab Administration
(A) Meta-analysis of major adverse cardiac events (MACE). Meta-analysis results of all available studies reporting on long-term clinical follow-up (MACE), showing a trend toward
a lower incidence of MACE in intracoronary (IC) versus intravenous (IV) abciximab bolus administration (nonstatistically signiﬁcant). (B) Meta-analysis of death. Meta-analysis
results of all available studies reporting on long-term mortality showing a trend toward a lower incidence of MACE in IC versus IV abciximab bolus administration (nonstatistically
signiﬁcant). (C) Inﬂuence of left ventricular ejection fraction (LVEF) on MACE reduction after IC abciximab. Meta-regression showing a signiﬁcant interaction between the mean
LVEF and the decrease in MACE incidence in the same studies reported in A.
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1341quantitative interaction (5), the principle that the beneﬁt of a
treatment is greater in high-risk patients.Salvatore De Rosa, MD, PhD
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